STOCK TITAN

Codex DNA to Present at the 2022 Jefferies Healthcare Conference

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Codex DNA (Nasdaq: DNAY) will present at the 2022 Jefferies Healthcare Conference on June 10 at 9:00 AM Eastern Time. The presentation will be available via live webcast on the company's investor relations page. An archived version will be accessible for 30 days post-event. Codex DNA specializes in automated synthetic biology systems, enabling rapid and error-free DNA and mRNA synthesis. Their innovative BioXp™ system is transforming workflows in precision medicine, drug discovery, and gene therapy.

Loading...
Loading translation...
Argus Session date unavailable
+2.29% session move Open Argus
Details

News Market Reaction – DNAY

The recorded move for DNAY in the trading session of this news was +2.29%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Friday, June 10th at 9:00 am Eastern time / 6:00 am Pacific Time.

The presentation will be webcast live and can be accessed through a link on the investors section of Codex DNA’s website at https://ir.codexdna.com. An archived replay of each webcast will be available for 30 days following the event.

About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Contact:
Richard Lepke
Director of Investor Relations
(619) 840-5392
RichardL@codexdna.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Codex DNA's presentation at the Jefferies Healthcare Conference?

Codex DNA's presentation will be on June 10, 2022, at 9:00 AM Eastern Time.

How can I watch Codex DNA's presentation at the conference?

The presentation will be webcast live on the investors section of Codex DNA's website.

What technology does Codex DNA offer for DNA synthesis?

Codex DNA offers the BioXp™ system, which automates and optimizes the synthesis and cloning of DNA and mRNA.

What markets does Codex DNA serve with its technology?

Codex DNA serves various markets including precision medicine, biologics drug discovery, and gene therapy.

What is the ticker symbol for Codex DNA?

The ticker symbol for Codex DNA is DNAY.

Keep reading